Stem cells injected into ALS patients in first human trial
NCT ID NCT07118319
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests whether injecting lab-grown nerve cells (made from stem cells) into the spinal cord is safe for people with ALS, a fatal disease that destroys movement control. Twelve participants will receive the cells either once or four times over six months. The main goal is to check for side effects, not yet to prove it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iPSC-derived motor neuron progenitor cells (XS228CN)
What this could lead to
If safe and effective, this could point toward a cell-replacement therapy to slow or halt ALS progression.
What could go wrong
This is a very early Phase 1 trial with only 12 participants, focused on safety. It may not show any benefit, and cell therapies carry risks like immune rejection or tumor formation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Third Hospital
RECRUITINGBeijing, Beijing Municipality, 100191, China
Contact Phone: •••-•••-•••• Email: •••••@•••••